Notably, the combination of eplerenone and enalapril pronounced their antihypertensive and anti-remodelling effects.126 Additionally, among 52 patients with TRH, eplerenone at average 70 mg/day significantly decreased clinic systolic BP by 17.6 mmHg and 24-h mean systolic BP by 12.2 mmHg over 12 weeks.127 In a meta-analysis of 5 trials including 1437 patients with hypertension (8–16 weeks), eplerenone 50–200 mg/day vs placebo decreased systolic BP by 9.21 mmHg, with no significant difference across these doses, while a dose of 25 mg/day showed no significant BP reduction.128. The gene discussed is TRH; the disease is hypertensive disorder.